Key result
Improved AAV vector design and manufacturing can enhance gene therapy efficacy for atrial cardiomyopathy.
Why the study?
Gene therapies offer the potential to treat atrial cardiomyopathy at the root cause, but advancements in vector design, manufacturability, and suitability are needed to enhance efficacy and accessibility.
rAAV-based gene therapies offer a potential root-cause treatment for atrial cardiomyopathy, though significant translational obstacles remain.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in atrial cardiomyopathy; extends vector research but remains hypothesis-generating.
INTRODUCTION: Atrial cardiomyopathy (ACM) is characterized by complex interactions involving molecular, electrical, and structural abnormalities that predispose individuals to cardiac dysfunction and stroke. Current treatments are effective at managing the complications of ACM, but lack the ability to correct the underlying atrial substrate driving the disease state. Alternative treatment modalities are required to address this shortfall with viral-based delivery methods, particularly recombinant adeno-associated viral vectors (rAAVs), being at the forefront of filling this unmet need. Research in the design of rAAVs targeting the atrial myocardium has demonstrated robust atrial transduction with minimal toxicity. Despite the technology's promise, various biological, immunological, and economic obstacles continue to challenge the clinical translation of rAAVs targeting ACM. AREAS COVERED: In this review, the concept of ACM is summarized along with its common sequelae and current management. Following this, a basic overview of rAAV biology is provided alongside a narrative review of research investigating rAAV-based gene therapy targeting atrial myocardium in preclinical models. EXPERT OPINION: Gene therapies provide an opportunity to treat ACM at the root cause beyond the management of its sequelae. However, solutions aiming to improve vector design, manufacturability and suitability for ACM should be adopted to improve therapeutic efficacy and broaden patient accessibility.
No takes yet. Share an insight, caveat, or question.
Hammoud et al. (2025) conducted a review in Atrial cardiomyopathy. Recombinant adeno-associated viral vectors (rAAVs) was evaluated. Recombinant adeno-associated viral vectors targeting the atrial myocardium demonstrate robust atrial transduction with minimal toxicity in preclinical models of atrial cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: